Our strategy has
two elements. Firstly, to complete development of alicaforsen
enema (see below) for ulcerative colitis and pouchitis ahead of
international marketing approvals and commercialisation.
Secondly, to acquire other late stage development, or already
marketed, specialist products and companies that the team can
apply their skills and experience to for the benefit of patients
and other stakeholder groups.
We will build
value for shareholders by targeting hospital-treated medical
conditions that fall outside the focus of large global
pharmaceutical companies. The hospital specialist sector which
is $160bn globally per annum and is showing one of the highest
growth rates in the pharmaceutical industry. Our focus is on
products that are intended to address the unmet clinical needs
of small patient populations.
instances drugs for small patient populations can be ‘fast
tracked’ through marketing approvals where adoption of new
products is driven by unmet or poorly satisfied patient needs.
Patients with this kind of need are usually managed in
specialist centers and hospitals in Europe and the United
Team have a track record of
identifying products that meet our licensing and acquisitions
criteria. The Management Team’s activity is supported by
renowned advisors, both commercial and scientific, and a board
of directors chaired by former London Stock
Exchange CEO, Richard Wood.